Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FYI;(Bioserve),
“With the addition of the Genomic Collaborative bio-bank to the company’s comprehensive services, BioServe is on track to become the leader in helping researchers discover and validate a new generation of superior diagnostic and therapeutic targets,” Dr. Krenitsky says. The company currently employs about 55 in Beltsville and its recently opened facility in Hyderabad, India, which is primarily engaged in serving the molecular and genetic diagnostics market in that country. Revenues last year were “just south” of $10 million, Krenitsky notes, and the company is profitable. "
shareholders -Million $ quest-> number of shares
Good Luck All!!
1 Adenovir: 1.010.000 -- 1mil bucks at .99 per share.
2 ancient/holder: 1.000.000 --1dollar
3 ann441j: 1.525.000 -- 65.5cents
4 Athomedad2: 20.500 -- 48.78dollars
5 brian1993: 1.959.600 -- 51cents
6 Brothers In Arms: 1.956.000 -- 51cents
8 chrisbaskett: 1.324.000 -- 75cents
9 coffee880: 5.000.000 -- 20cents
10 cottonmather: 890.000 -- 1.123dollars
11 dmceng: 1.000.000 -- 1 dollar
12 ExtremeSport: 507,000 - 1.97dollars
13 FSAIL52: 500.000 -- 2bucks
14 goliath65: 7.358.910 -- ***.1359CENTS***
15 hvs1: 1.000.000 -- 1dollar
16 indy51 550.000 -- 1.81dollars
17 jever0 4.000.000 -- 25cents
18 johnnyfiber: 1.400.000 -- 71cents
19 johnsbus: 307.744 -- 3.257dollars
20 linkerboy: 1.000.000 -- 1dollar
21 loch3 100.000 -- 10dollars
22 madcabbage 1.080.000 -- .92cents
23 mbmun: 480.000 -- 2.08dollars
24 mcmartinhall: 800.000 -- 1.25dollars
25 Michiko : 990.000 -- 1.01dollars
26 Natures Way: 3.400.000 -- 29cents
27 oncomi: 1.300.000 -- 76cents
28 pma_56: 111.745 -- 8.98dollars
29 red_tag_ed: 8.000.000 -- ***12.5CENTS***
30 rveach: 1.300.000 -- 77cents
31 RoyalDutchman: 3.600.000 - 27cents
32 sam: 1.600.000 -- 62.5cents
33 Sandoz 1.323.600 -- 75.5cents
34 steinburger: 1.085.000 -- 92.1cents
35 stockholder101: 7.684.000 -- **13.01cents**
36 stockmania: 606,200 -- 1.65dollars
37 supiedupie: 200.000 -- 5 dollars
38 TheBigLab: 70.000 -- 14.28dollars
39 trebeg: 1.600.000 -- 62.5cents
Kids...
Yeah, Dutchess isn't pretty. But it is better than what we were dealing with, such as La Jolla and the guys before them, and they REALLY took DNAP for a ride. I don't think Richard had much choice. It goes w/out saying he would of done better if he could sell it, which obviously is happening now. There just HAS to be proof of substantial revenues just around the corner to lay on the table to financiers.
Another note. Previous to the R.Gabriel era Frudakis et al did not really know how to handle public relations. They talked too much about everything. After all, Frudakis is a scientist, not a person who regularly dealt with bottom dwellers and people barking for results and answers. But he also had no choice until he had the $$ and the right man. I think Hector helped him find the right guy; Richard.
All three of them make about 200+ K a year. Find an experienced CEO in this realm and try to pay them that much.
When Gabriel came on, the information went from spotty and wishful to just post-factual and bone dry, as it should be IMO. The first thing a responsible CEO does for his shareholders is take off the icing and start from scratch. The angst will dissipate, and real news will speak for itself.
There are too many entities out there who have gorilla bucks and would either like to scrunch DNAG or take their pipeline out of competition, or just take them, period.
Therefore it is of the highest priority to protect all relations and agreements with other companies until the deals are sealed. Also, throw in the tiny share price and control/takeover becomes a concern. Where are those other 500 million shares?
The officers don't have that many.
If you read your post, you will see that you are talking about a typical ground floor company in it's first years.
It has followed the process that I have witnessed a hundred times. And that is why I take exception it has lasted 7 years.
I would really like to see this company make it, and I think they deserve it.
Ciao
Genentech's (DNA) :
Sales(last 12 mo's): 11 Billion
Net Income: 747 Million
Last EPS(Q2,07) .78 p/s
Float: 461 Mil
Outstanding Sh: 1.1 Billion
Just a look at the other end.....
Can Genentech Stage a Recovery?
Biotech Firm's Shares May Languish in Sick Bay
Unless Pipeline, Tanox-Deal Prospects Improve
By KAREN RICHARDSON
July 23, 2007; [WSJ] Page C1
Genentech Inc.'s stock could use a shot in the arm.
The once-healthy stock of the San Francisco biotechnology company could languish for months as sales growth slows for its key cancer drug, Avastin. And new revenue opportunities for its existing stable of medicines likely won't materialize until at least the end of the year.
What investors once viewed as a potential catalyst -- Genentech's first acquisition -- also has turned out to be more of a pain than a salve. Stumbles over regulatory issues have delayed the closing of the agreement to buy Tanox Inc., a small biotech company that makes an asthma drug. And some bearish investors have speculated that the $919 million transaction might never get done.
Since hitting a high of nearly $100 in 2005, Genentech shares have drifted lower. In 4 p.m. New York Stock Exchange composite trading Friday, the stock closed down two cents at $75.15, giving the company a market value of $79 billion. The shares are down 7.6% this year and off 19% since the end of 2005, while the Dow Jones Wilshire Biotechnology Index is effectively flat over both time periods.
Having traded in 2003 at more than 200 times earnings, Genentech, whose majority owner is Swiss drug maker Roche Holding AG, is now priced at about 25 times estimated per-share earnings for 2007, while the broader biotechnology sector is trading at 53 times, according to Thomson Financial.
While Genentech is inexpensive on a historical basis, "a cheap-looking valuation can be a trap before new growth drivers emerge," warns Jim Reddoch, an analyst at Friedman Billings Ramsey & Co., which doesn't provide banking services for Genentech. Mr. Reddoch has a "hold" rating on the stock. In investing parlance, a "value trap" is a stock that has gotten cheap but will languish at that valuation.
High biotech-stock valuations are "like a fire that needs more wood to keep it going," says Tom Vandeventer, portfolio manager at Tocqueville Asset Management LP, which manages about $7 billion. Tocqueville recently sold some Genentech shares, which Mr. Vandeventer bought a few years ago. "A lot of the catalysts that might move the stock higher are visible but aren't close at hand before year's end."
Avastin's second-quarter sales in the U.S. were flat from the previous quarter for its approved treatment for colon cancer. But Genentech expects Avastin's U.S. sales, which at $1.75 billion last year accounted for 23% of its total product sales, will be buoyed since the drug has been approved to treat lung cancer. Approval for the treatment of breast cancer is expected in mid-2008, which the company also expects to boost revenue.
Some analysts aren't so optimistic about Genentech's near-term growth prospects, however, and lament investors' fixation on Avastin as a driver of earnings and stock price. Instead investors need to look at Genentech's whole array of treatments.
"People need to come back to a more fundamental story, which is a portfolio of products," says Michael King Jr., an analyst at Rodman & Renshaw, a small investment bank that specializes in biotech stocks. Mr. King has a "hold" rating on Genentech. He doesn't own the stock and his firm doesn't have a banking relationship with Genentech.
One concern for investors is a study last month that indicated Avastin works marginally better when used in half the standard dose. Expecting that doctors will prescribe lower doses, investors bet sales would slow. Within three weeks of the study's disclosure, Genentech shares had fallen 6%.
Meanwhile, results of trials for Genentech's lymphoma drug, Rituxan, for treatment of rheumatoid arthritis and other diseases aren't due until the end of 2007 or later.
Even Genentech's first acquisition since it was founded 31 years ago has failed to inspire investors, save for short sellers betting that its stock price would decline and merger traders focused more on the target, Tanox.
The November announcement that Genentech would buy Houston-based Tanox for $20 a share caps an 11-year collaboration on Xolair, an injectible asthma drug. Last year, Genentech paid $187 million in royalties for Xolair, mostly to Tanox, and recorded Xolair sales in the U.S. of $425 million.
In January, Genentech said the review of the deal by the Federal Trade Commission would take longer and delay its closing date. Then, in February, the Food and Drug Administration said Xolair required a "black-box warning," the industry's most stringent, because it found Xolair caused a severe allergic reaction and even death in some patients, which could occur hours after an injection.
This month, Genentech said the strengthened warning label leaves the length of post-injection observation time to the discretion of doctors rather than mandating it, which could have been an inconvenient put-off for doctors and patients.
Still, sales growth of Xolair, which costs as much as $40,000 a year, had already been slowing. Sales grew 14% in the second quarter, compared with 31% in the same period in 2006.
"A lot of physicians and primary-care specialists aren't so comfortable administering it," says Jonathan Field, director of Pediatric Allergy & Immunology Clinic at New York University Medical Center. He adds, however, that he has 24 patients on the drug with no sign of any problems.
Other doctors and investors in Genentech and Tanox say the label issue was a temporary setback and that it will continue to be profitable for Genentech. By applying the new label and addressing the FDA's concerns, "we expect continued good growth in Xolair use," David Ebersman, chief financial officer of Genentech, said in an emailed response to questions.
With $1.75 billion in cash on its balance sheet in the second quarter, when it generated $760 million in cash from operations, Genentech won't be burdened by the financial cost of buying Tanox. Nor, however, would it necessarily hurt to walk away, since Genentech would only have to pay a relatively small $5 million break-up fee to Tanox to do so. Last month, about 20% of Tanox's shares were sold short.
Genentech's Mr. Ebersman said the company still expects the deal to close in the third quarter, subject to customary closing conditions, FTC approval and "the absence of a material adverse event," which the company defines as something that could hurt the sales, future value or revenue of Xolair -- a caveat so vaguely worded that it leaves both short sellers and long-term investors feeling queasy.
http://online
A reverse split can't happen. It would be the same as pulling the plug. We either make it by the end of the year or don't.
Period.
jkids210,
Good morning. My post to you wasn't really to answer your questions put to Stockboy. I had just noticed your inquiries and your post on what a friend said to you.
That aside, I am not 100 % positive that this company will succeed. And there are too many factors involved in the last 7 years to try and give you an idea why I have been buying shares all these years. I am not a scientist, especially in a cutting edge area of DNA research, so therefore you can assume that this is a gamble on this end.
Richard is somewhat of a geek. People need to get over that. His disposition has not kept him from keeping this company alive with such moves as the Biofrontera purchase and sale that made us a cool 7 million. Yes, he was an officer of that company, but that only helps. If you listen to his last presentation you will see he has a very good handle on financing for biotechs and is taking a global approach, which I find very relieving, as the American dollar and it's credit worthiness is in, let's say, "questionable reliability". If financing for an up-and-coming biotech is a risky business, it may be better to look for funds where the currency is strong.
I was here every day during the reverse split. I remember a lot of talk but I do know Frudakis didn't (and wasn't in the position to) emphatically promise no reverse. It doesn't matter anyway. There was no experienced CEO, DNAP financing was in the hands of sharks, and there was no other choice. You either trust Tony Frudakis or you don't. I do, and have never had a problem with that. And I have averaged down. I have also been buying the last two weeks at .0061 and now .006 every day, so I guess I am still averaging down.
We started a project with Moffitt several years ago. Too many coincidences have occurred that have led up to M2Gen. That is my reason for singling out Gomez. You and I both know how some agreements must be kept close to the sleeve, especially with large co's like Merck. There may be nothing there, but my opinion in there is. Tony said we were running genome work for 3 major companies. It goes on and on, but in the end, it is worth a half-cent bet to this guy. "If you don't have the gambling money stay out". I like the odds here compared to Las Vegas(and I have done good there too).
You can say the financing with Dutchess is a mess but you have no idea what it used to be like. It has improved markedly, in my opinion, yet DNAPrint is still at the mercy of not having large revenues, the basis for good financing.
It all comes down to the science. Will it sell and is it going to be usefull and applicable. Little signs from Trace genetics, Ellipsis, the FDA, and Moffitt tell me maybe so.
It's a bet. For sure.
But I like it.
Wish I could give you more, but as things come to me I will pass them on to you, O.K.?
Regards. And good luck to you.
frenchee
You need to reduce the size of your graphs above....
Good news out today.
Howdy all,
I have been buying shares of this company for my employees and relatives for over a year now. My best price was around 40 cents. But I didn't get any for myself until last month. What a kick. Been buying SPIRE for almost ten years. But this is my new baby.
Things look real good with this company. Good luck to you all.
jkids210,
It is obvious by your inquiries both here and other places that this company intrigues you. To you, I suppose, it is either a diamond in the rough, awaiting it's explosion onto the marketplace after 7 long years; or it is an entity in it's final throes that just didn't die when it was a couple years old. Some would say, (including our local naysayer and bio-medically-uneducated Stockboy)that the principals of this company are theives and are just sucking all the blood out of it. You will get the same response from the super-intelligent Frogdreaming.
It says in your profile that you are an investor in Biomedical companies and that you like to watch small companies with undervalued potential. It seems you work in the business management and financial world. Therefore you yourself may have the best chance at evaluating DNAPrint's future and potential.
Keeping in mind that DNAPrint came into the scene at the end of the dot-com craze and that the biotech sector has been in limbo for several years, this fledgling company is in a category you are familiar with; one that takes years to develop successful biomedical research that leads to product
efficacy and marketing, not to mention pharmeceutical applications that take kazillions of dollars and years upon years of FDA process and testing.
I myself have never had a problem with the management or administration of this company. Suffice it to say that I have been an officer of several companies in a very difficult industry after 40 years of management. I knew from the start that DNAPrint was not going to be the instant speculative buy that this OTC-BB has a plethora of.
On one hand, DNAPrint can easily be a disappointment to all who have invested over the 7 years and have seen the value of their original pink-sheet baby dwindle with a reverse and little revenue.
On the other hand, and this is just personal opinion, it is amazing to me that this company has survived past the deadly 5 year mark in an almost impossible sector, not exactly a break-into-and-survive environment, and found ways to sell what technology it does have while continuing research and development towards several projects, along with a very healthy relationship with the FDA.
You eyes should be on Hector Gomez. Get to know him a little better. His relationship with Merck. Also, don't fall into the trap of looking at this stock through blue-chip glasses. After all, it is one half of a penny a share.
Good luck.
hee hee.......
Sorry Froggie,
Grasp at another straw......
Froggie and Johnny,
Stop crying like little babies. Shelly removed a post of mine that was no worse.
It is obvious Precious didn't remove that post "because he didn't like it". You people have hand picked your "post of the year" and decided to burn a cross. Get over it. If you want perfection, go look in the mirror. LOLOL!
PL1,
It may take several years to identify a poster's agenda as conspicuously deceptive, and that is my personal opinion of what Frogdreaming is all about. This just goes to show that the truth always comes out.
Your mediation on this board has been fair and non-prejudice.
I have had my own posts deleted. I asked for it, basically.
You have not been bias either for or against polarized opinions of this company. You have followed the reasonable guidelines set forth for all to see.
The post berating your service here by Frogdreaming is untrue and a desperate outlashing in defense of his agenda to harm DNAPrint, for whatever reason.
Keep doing a good job, and thank you.
Then you are, quite plainly, a coward and a slanderer.
Kids,
DNAPrint is alive today and not selling shares as a result of Gabriel's deal with Biofrontera. Research that little feat.
Stockboy.
Are you calling Tony Frudakis a thief?
Please elaborate.
Flip
I am glad you are ten steps ahead.
Now, be eleven steps ahead and take a chill pill.
Maybe Preciouslife1 can expound on the sad state of storefront affairs when he gets back.
After all, he seems to have frequent contact and access to Mr Gabriel.
It can't cost THAT much to spruce things up a bit.
Flip,
With all due respect to your disappointment with DNAPrint, I think that your venting
here won't really bring you any satisfaction in the long run. Even if you have sold your shares, it just can't be healthy to languish in your own frustration by taking it out here.
I for one do not agree with your stance on R. Gabriel. But that is just my opinion. I am sorry your patience has not been rewarded. Good luck to you.
And maybe you should stop in at DNAPrint since you pass by occasionally, tell them you are a shareholder, and ask what's with the sign. After all, you paid for a fraction of it.
I just checked out the slides from the presentation for Income statements and cash flow(projected).
What is interesting is a projected jump in revenues next year (08) to 5.7 million and then to 18 mil in '09.
Is this a clue as to work with Moffit?
We shall see.
1bigbang,
I concur. Thanks for the input.
cheers.
Howdy Chris,
Yes, in some ways it seems forever and an insurmountable task, especially to those of us who have been here awhile.
But the truth of it is, the get-rich quick fallacy is just that. It still takes lots of bucks and lots of research to be viable and the rewards are potentially huge. Financing will give us the $$ needed to continue on the path and continue the research in other projects too.
I got the impression that R.G. isn't fooling himself and is well aware of the pitfalls and rungs of the ladder needed to climb to get that money. Once that happens, things will change, and markedly so. Here comes the Euro!
Good luck to us!
Hi David,
I guess it's not surprising that some people get all hyped up about anything that might mean news. But this was a presentation meant solely for the purpose of exposing the company to funding opportunities, and he did his job well.
The MM's know better also.
Good opportunity to get cheap shares.
S101....
I listened to the presentation in whole.
Richard took a different tact by beginning his talk with a layout of how financing a biotech should take place, and the difficulties that lie therein. He used Biofrontera and the european(german) financing as examples. It was actually quite informative, and the processes along with the approach to eventual bonding need to be very well planned for a biotech
without alot of cash flow, and one of his points was that the situation with the dollar makes eurpean financing look more attractive all the time.
All else was the same; bridge financing, timelines etc.
Then he went into DNAPPharm's two main products, the timeline(2008-2010) and used a conservative spreadsheet to show costs/research/sales thru the next 4 years.
His one main figure for a bond and stockbuyback by 2011 was a overall 50 million dollars. I suppose that meant the amount after the bridge financing and to get us to an IPO by 2011, if not sooner.
He mentioned the IPO and stock buyback twice, but aftre sales begin of our two products.
Sorry, but I'm in a hurry.
I thought it was a good presentation.
He is very keen on financing.
BTW, Cananda just matched our dollar with theirs for the first time in 30 yrs. Looking overseas for our financing is astute and a no-brainer, but is a lot more work for R.G., but he's happy to do it.(travel)
ciao
O.T.;
I am leaving now to go play golf in a fundraiser for own local volunteer fire department.
If Froggie calls, please put him on hold while I do something POSITIVE.
And to everyone else; give a little. It comes back big. Enjoy the sun, fellow penny-peons!
Froggie,
Please, oh great one who denigrates DNAG, tell us what exactly what you mean by "every month", and how much that adds up to:
"In the last three years DNAG has spent about the same amount of money per year on it's flagship Statnome project as it spends on management salaries every single month."
Your point is not only meaningless, you are pulling dead rabbits out of a hat and your little magician show has long-lost it's luster.
They have never claimed Statnome to be their "flagship".
Management is doing it's job by putting resources where they can develop the most and efficient results within time frames.
And that applies fluidly to MANY projects.
They are running the company; before you, during you, and long after you sit on the sidelines throwing pebbles from behind an empty trashcan.
I picked up 1.6 M shares today. Guess no one else wanted any at .0061.
What the heck, life is short.
no kidding......
O.T., preciouslife1....
Just wanted to make sure you read my last post to you and that we are on an even keel.
Thanks and good day.
PL1
Sorry for the misinterp.....
I meant for someone to judge YOU for not getting results on financing was ridiculous.
I was speaking about all of the negative posting, NOT to you as a person. It was
phrases aimed not at you and was thanking you for your input. LOL Please read again!
Thank you PL1 for reiterating my point, albeit unintentional.
Judge not, lest you be judged.
Ridicule is so easy, yet getting up off your arse seems to be a whole other matter....
Ciao
There is a saying that a watched pot never boils.
For all of you that decide to hang on to your shares yet are also complaining,(and badmouthing)the company, I am in awe as to the reason you may find this of any redeeming value whatsoever. I would like to be enlightened as to any benefit I may have missed that you gain by taking frustrations and impatience out on what are actually your own decisions.
I do not mean to be hard on anyone here, just wondering why people can keep their investment at hand and yet do nothing but hurt it by ridicule on a public forum.
I was under the impression that life is too short to dwell on our percieved mistakes or plain bad luck. Yet it appears that
some here may find out too late in life that it never does any good to complain without offering any recourse or positive energy.
Good luck to you all. I will be buying more next week.
Frogster,
I wasn't there. You weren't there.
And for those who weren't, that makes it heresay at best, and it makes no sense whatsoever for others to get involved, or shall I say take a cheap shot from the sidelines the minute an opportunity to bash Frudakis arises.
If I am wrong, then you have my most sincere dripping apology smathered with the deepest regret that flows from the very essence of my most humble being.
Over and out.
It's nice to know you attended the meeting, Froggie. Since you are in the position of claiming who has a more accurate story, albeit one that criticizes Frudakis as usual, please tell us how you take heresay and bend it into your form of "the truth" and then apply it to the rest of the world.
What magnificent magic you have, lilypad prince.
May 22, 2007 - 23andMe, Inc., a privately held, early stage personal genetics company today announced it had closed its Series A Preferred Stock Financing, which included investments from, among others, Genentech, Inc., Google Inc., MDV-Mohr Davidow Ventures and New Enterprise Associates.
Terms of the financing were not disclosed
O.T.:
The best and only way for you to help improve this board would be to take your special talent of ambiguity along with the agenda you administer and take it elsewhere. It's not just anti-DNAPrint, it is your incessant constription to creating argument and disruption through animosity.
The Frog wears no clothes.
MattG....
Oh no.........Thank YOU!!!
Matt....
Then why did you suggest it?
Bag,
No sweat. Your response wasn't playing on his terms anyway. Nice job.
I have ignored his return postings many times, and for my own chuckle have not even read them.
I will not be badgering his highness any longer, though, as someone is making an effort to clean this place up.
The froglegs have been sufficiently barbecued anyway.
Cheers!
Bag,
I am sure everyone else here understands your point.
It is Frog's job to throw salt on innovative thinking when it comes to DNAPrint.
You will notice he doesn't bother with Stocky and his over-zealous enthusiasm.
It is only when anything positive about the science is proposed, he is all over it. It's his job.
But many of us understand the meaning of DISCOVERY.
As my brother would say, "Please don't feed the animals".
Ciao